Physician profile
David C Smith
NPI 1093767865
$622.01
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $225.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $156.40 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $128.24 | 2019 | |
| Shire North American Group INC | $53.50 | 2019 | |
| Ethicon US, LLC | $44.64 | 2019-2020 | |
| Acell, INC. | $34.74 | 2020 | |
| Z-Medica, LLC | $34.47 | 2020 | |
| Mallinckrodt Hospital Products INC. | $33.90 | 2020 | |
| Merck Sharp & Dohme LLC | $29.31 | 2020 | |
| Medtronic USA, INC. | $25.76 | 2020 | |
| Allergan, INC. | $23.17 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $23.05 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $17.51 | 2019 | |
| Medline Industries LP | $17.32 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.